Literature DB >> 22706086

CD2AP/SHIP1 complex positively regulates plasmacytoid dendritic cell receptor signaling by inhibiting the E3 ubiquitin ligase Cbl.

Musheng Bao1, Shino Hanabuchi, Valeria Facchinetti, Qiumei Du, Laura Bover, Joel Plumas, Laurence Chaperot, Wei Cao, Jun Qin, Shao-Cong Sun, Yong-Jun Liu.   

Abstract

The human plasmacytoid dendritic cell (pDC) receptor BDCA2 forms a complex with the adaptor FcεR1γ to activate an ITAM-signaling cascade. BDCA2 receptor signaling negatively regulates the TLR7/9-mediated type 1 IFN responses in pDCs, which may play a key role in controlling self-DNA/RNA-induced autoimmunity. We report in this article that CD2-associated adaptor protein (CD2AP), which is highly expressed in human pDCs, positively regulates BDCA2/FcεR1γ receptor signaling. By immunoprecipitation and mass spectrometry analyses, we found that CD2AP bound to SHIP1. Knockdown of CD2AP or SHIP1 reduced the BDCA2/FcεR1γ-mediated ITAM signaling and blocked its inhibition of TLR9-mediated type 1 IFN production. Knockdown of CD2AP or SHIP1 also enhanced the ubiquitination and degradation of Syk and FcεR1γ that was mediated by the E3 ubiquitin ligase Cbl. This led us to discover that, upon BDCA2 cross-linking, the CD2AP/SHIP1 complex associated with Cbl and inhibited its E3 ubiquitin ligase activity. In human primary pDCs, cross-linking of the BDCA2/FcεR1γ complex induced the recruitment of the CD2AP/SHIP1/Cbl complex to the plasma membrane of pDCs, where it colocalized with the BDCA2/FcεR1γ complex. Therefore, CD2AP positively regulates BDCA2/FcεR1γ signaling by forming a complex with SHIP1 to inhibit the E3 ubiquitin ligase Cbl.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22706086      PMCID: PMC3665352          DOI: 10.4049/jimmunol.1200887

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  The nature of the principal type 1 interferon-producing cells in human blood.

Authors:  F P Siegal; N Kadowaki; M Shodell; P A Fitzgerald-Bocarsly; K Shah; S Ho; S Antonenko; Y J Liu
Journal:  Science       Date:  1999-06-11       Impact factor: 47.728

2.  Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus.

Authors:  Sean R Christensen; Jonathan Shupe; Kevin Nickerson; Michael Kashgarian; Richard A Flavell; Mark J Shlomchik
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

3.  The adaptor molecule CIN85 regulates Syk tyrosine kinase level by activating the ubiquitin-proteasome degradation pathway.

Authors:  Giovanna Peruzzi; Rosa Molfetta; Francesca Gasparrini; Laura Vian; Stefania Morrone; Mario Piccoli; Luigi Frati; Angela Santoni; Rossella Paolini
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

Review 4.  IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors.

Authors:  Yong-Jun Liu
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

5.  Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells.

Authors:  Laurence Chaperot; Ariane Blum; Olivier Manches; Gabrielle Lui; Juliette Angel; Jean-Paul Molens; Joël Plumas
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

6.  The inositol 5'-phosphatase SHIP binds to immunoreceptor signaling motifs and responds to high affinity IgE receptor aggregation.

Authors:  M A Osborne; G Zenner; M Lubinus; X Zhang; Z Songyang; L C Cantley; P Majerus; P Burn; J P Kochan
Journal:  J Biol Chem       Date:  1996-11-15       Impact factor: 5.157

Review 7.  The emerging role of interferon in human systemic lupus erythematosus.

Authors:  Emily C Baechler; Peter K Gregersen; Timothy W Behrens
Journal:  Curr Opin Immunol       Date:  2004-12       Impact factor: 7.486

8.  The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1).

Authors:  Satsuki Kobayashi; Asako Sawano; Yoshihisa Nojima; Masabumi Shibuya; Yoshiro Maru
Journal:  FASEB J       Date:  2004-03-04       Impact factor: 5.191

Review 9.  The central role of dendritic cells and interferon-alpha in SLE.

Authors:  Virginia Pascual; Jacques Banchereau; A Karolina Palucka
Journal:  Curr Opin Rheumatol       Date:  2003-09       Impact factor: 5.006

10.  Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production.

Authors:  Wei Cao; David B Rosen; Tomoki Ito; Laura Bover; Musheng Bao; Gokuran Watanabe; Zhengbin Yao; Li Zhang; Lewis L Lanier; Yong-Jun Liu
Journal:  J Exp Med       Date:  2006-05-30       Impact factor: 14.307

View more
  24 in total

1.  Differential Recognition Preferences of the Three Src Homology 3 (SH3) Domains from the Adaptor CD2-associated Protein (CD2AP) and Direct Association with Ras and Rab Interactor 3 (RIN3).

Authors:  Evgenia Rouka; Philip C Simister; Melanie Janning; Joerg Kumbrink; Tassos Konstantinou; João R C Muniz; Dhira Joshi; Nicola O'Reilly; Rudolf Volkmer; Brigitte Ritter; Stefan Knapp; Frank von Delft; Kathrin H Kirsch; Stephan M Feller
Journal:  J Biol Chem       Date:  2015-08-20       Impact factor: 5.157

2.  Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab.

Authors:  Michelle A Gill; Andrew H Liu; Agustin Calatroni; Rebecca Z Krouse; Baomei Shao; Allison Schiltz; James E Gern; Alkis Togias; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2017-09-01       Impact factor: 10.793

Review 3.  The multifaceted biology of plasmacytoid dendritic cells.

Authors:  Melissa Swiecki; Marco Colonna
Journal:  Nat Rev Immunol       Date:  2015-07-10       Impact factor: 53.106

4.  Targeted genetic analysis of cerebral blood flow imaging phenotypes implicates the INPP5D gene.

Authors:  Xiaohui Yao; Shannon L Risacher; Kwangsik Nho; Andrew J Saykin; Ze Wang; Li Shen
Journal:  Neurobiol Aging       Date:  2019-06-18       Impact factor: 4.673

5.  Modulation of dendritic cell innate and adaptive immune functions by oral and sublingual immunotherapy.

Authors:  Pamela A Frischmeyer-Guerrerio; Corinne A Keet; Anthony L Guerrerio; Kristin L Chichester; Anja P Bieneman; Robert G Hamilton; Robert A Wood; John T Schroeder
Journal:  Clin Immunol       Date:  2014-08-27       Impact factor: 3.969

Review 6.  Microglial malfunction: the third rail in the development of Alzheimer's disease.

Authors:  Siddhita D Mhatre; Connie A Tsai; Amanda J Rubin; Michelle L James; Katrin I Andreasson
Journal:  Trends Neurosci       Date:  2015-10       Impact factor: 13.837

Review 7.  Regulation of TLR7/9 signaling in plasmacytoid dendritic cells.

Authors:  Musheng Bao; Yong-Jun Liu
Journal:  Protein Cell       Date:  2012-11-07       Impact factor: 14.870

8.  Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities.

Authors:  Matthew D Blunt; Stephen G Ward
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

9.  CD2-associated protein regulates plasmacytoid dendritic cell migration, but is dispensable for their development and cytokine production.

Authors:  Subhashini Srivatsan; Melissa Swiecki; Karel Otero; Marina Cella; Andrey S Shaw
Journal:  J Immunol       Date:  2013-11-11       Impact factor: 5.422

10.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.

Authors:  J C Lambert; C A Ibrahim-Verbaas; D Harold; A C Naj; R Sims; C Bellenguez; A L DeStafano; J C Bis; G W Beecham; B Grenier-Boley; G Russo; T A Thorton-Wells; N Jones; A V Smith; V Chouraki; C Thomas; M A Ikram; D Zelenika; B N Vardarajan; Y Kamatani; C F Lin; A Gerrish; H Schmidt; B Kunkle; M L Dunstan; A Ruiz; M T Bihoreau; S H Choi; C Reitz; F Pasquier; C Cruchaga; D Craig; N Amin; C Berr; O L Lopez; P L De Jager; V Deramecourt; J A Johnston; D Evans; S Lovestone; L Letenneur; F J Morón; D C Rubinsztein; G Eiriksdottir; K Sleegers; A M Goate; N Fiévet; M W Huentelman; M Gill; K Brown; M I Kamboh; L Keller; P Barberger-Gateau; B McGuiness; E B Larson; R Green; A J Myers; C Dufouil; S Todd; D Wallon; S Love; E Rogaeva; J Gallacher; P St George-Hyslop; J Clarimon; A Lleo; A Bayer; D W Tsuang; L Yu; M Tsolaki; P Bossù; G Spalletta; P Proitsi; J Collinge; S Sorbi; F Sanchez-Garcia; N C Fox; J Hardy; M C Deniz Naranjo; P Bosco; R Clarke; C Brayne; D Galimberti; M Mancuso; F Matthews; S Moebus; P Mecocci; M Del Zompo; W Maier; H Hampel; A Pilotto; M Bullido; F Panza; P Caffarra; B Nacmias; J R Gilbert; M Mayhaus; L Lannefelt; H Hakonarson; S Pichler; M M Carrasquillo; M Ingelsson; D Beekly; V Alvarez; F Zou; O Valladares; S G Younkin; E Coto; K L Hamilton-Nelson; W Gu; C Razquin; P Pastor; I Mateo; M J Owen; K M Faber; P V Jonsson; O Combarros; M C O'Donovan; L B Cantwell; H Soininen; D Blacker; S Mead; T H Mosley; D A Bennett; T B Harris; L Fratiglioni; C Holmes; R F de Bruijn; P Passmore; T J Montine; K Bettens; J I Rotter; A Brice; K Morgan; T M Foroud; W A Kukull; D Hannequin; J F Powell; M A Nalls; K Ritchie; K L Lunetta; J S Kauwe; E Boerwinkle; M Riemenschneider; M Boada; M Hiltuenen; E R Martin; R Schmidt; D Rujescu; L S Wang; J F Dartigues; R Mayeux; C Tzourio; A Hofman; M M Nöthen; C Graff; B M Psaty; L Jones; J L Haines; P A Holmans; M Lathrop; M A Pericak-Vance; L J Launer; L A Farrer; C M van Duijn; C Van Broeckhoven; V Moskvina; S Seshadri; J Williams; G D Schellenberg; P Amouyel
Journal:  Nat Genet       Date:  2013-10-27       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.